Mylan N.V. (MYL) : 9 analysts are covering Mylan N.V. (MYL) and their average rating on the stock is 2.33, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 6 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Mylan N.V. (MYL) has been rated by 6 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $66 and the lowest price target forecast is $52. The average forecast of all the analysts is $58.5 and the expected standard deviation is $6.02.
For the current week, the company shares have a recommendation consensus of Buy. Also, Brokerage firm Leerink Swann maintains its rating on Mylan N.V. (NASDAQ:MYL). As per the latest information, the brokerage house raises the price target to $55 per share from a prior target of $51. The shares have been rated Outperform. The rating by the firm was issued on August 15, 2016.
Mylan N.V. (NASDAQ:MYL): stock was range-bound between the intraday low of $40.21 and the intraday high of $40.88 after having opened at $40.84 on Wednesdays session. The stock finally closed in the red at $40.84, a loss of -0.22%. The stock remained in the red for the whole trading day. The total traded volume was 6,903,937 shares. The stock failed to cross $40.88 in Wednesdays trading. The stocks closing price on Thursday was $40.4.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.